CCA
XBI icon

Column Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Column Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$2.92K Hold
40
– – ﹤0.01% 649
2023
Q2 		$3.33K Hold
40
– – ﹤0.01% 659
2023
Q1 		$3.05K Buy
+40
New +$3.32K ﹤0.01% 689

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Column Capital Advisors's XBI Position: Q3 2023 in Review

Column Capital Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2023 at 40 shares worth $2.92K. The position accounts for ﹤0.01% of the portfolio, ranked #649.

Column Capital Advisors first reported a position in XBI in Q1 2023 and has held it in 3 quarters since. The position peaked at $3.33K in Q2 2023. 677 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

  • Column Capital Advisors held 40 shares of State Street SPDR S&P Biotech ETF worth $2.92K as of Q3 2023.
  • Column Capital Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2023.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #649 holding.
  • Column Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and has held it in 3 quarters since.
  • Column Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $3.33K in Q2 2023.
  • 677 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.